GlobeNewswire Inc | Mar 16, 2021 07:46AM EDT

March 16, 2021

SOUTH SAN FRANCISCO, Calif., March 16, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company committed to developing and commercializing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (CNS) disorders, today announced that Shawn Singh, VistaGens Chief Executive Officer, will participate in the following investor conferences in March:

Maxim Group and M-Vest?s Inaugural Emerging Growth Virtual ConferenceDates: March 17^th ? 19^thFormat: Corporate Presentation & One-on-One Fireside Chat Date: Friday, March 19^th at 1:00 p.m. ETFormat: Fireside Chat with Jason McCarthy, Research AnalystWebsite: To attend the virtual conference, register here https://www.m-vest.com/events/2021-emerging-growth-virtual-conference

Benzinga Biotech Small Cap ConferenceDate: Thursday, March 25^th at 10:05 a.m. ETFormat: Corporate PresentationWebsite: To attend the virtual conference, register here https://events.benzinga.com/ registration-page16068526119171607978331877

For more information regarding the conferences, please visit the sponsor conference websites.

About VistaGenVistaGen Therapeutics is a biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety, depression, and other CNS disorders. Each of VistaGen's three drug candidates has a differentiated potential mechanism of action, has been well-tolerated in all clinical studies to date and has therapeutic potential in multiple CNS markets. For more information, please visit www.vistagen.com and connect with VistaGen on Twitter, LinkedIn, and Facebook.

Company ContactMark A. McPartlandVistaGen Therapeutics, Inc.Phone: +1 (650) 577-3600Email:IR@vistagen.com